Cargando…

Screening of Medications for Idiopathic Membranous Nephropathy Using Glomerular Whole-Genome Sequencing

OBJECTIVE: To explore medications that have a therapeutic effect on idiopathic membranous nephropathy (IMN) using the Gene Expression Omnibus (GEO), the Connectivity Map (CMap) database, and bioinformatics approaches. METHODS: IMN patients' glomerular whole-genome sequencing data were retrieved...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Yawei, Li, Yameng, Li, Wenpu, Xiao, Zhenwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023152/
https://www.ncbi.nlm.nih.gov/pubmed/35465008
http://dx.doi.org/10.1155/2022/9337088
_version_ 1784690273172848640
author Hou, Yawei
Li, Yameng
Li, Wenpu
Xiao, Zhenwei
author_facet Hou, Yawei
Li, Yameng
Li, Wenpu
Xiao, Zhenwei
author_sort Hou, Yawei
collection PubMed
description OBJECTIVE: To explore medications that have a therapeutic effect on idiopathic membranous nephropathy (IMN) using the Gene Expression Omnibus (GEO), the Connectivity Map (CMap) database, and bioinformatics approaches. METHODS: IMN patients' glomerular whole-genome sequencing data were retrieved and screened in the GEO database, differentially expressed genes were identified using GEO2R analysis, a PPI network was built in the STRING database, node degree values were calculated, and topological analysis was performed using the degree value to identify core genes. The WebGestalt database was used to perform GO enrichment and KEGG pathway analyses on the core genes. Candidate medications for the therapy of IMN were collected from the CMap database, and the candidate medications were then searched and analyzed. RESULTS: 113 core genes were identified by topological analysis from the 1157 genes that were shown to be differentially expressed. The enrichment analysis identified several important gene functions and signaling pathways related to IMN. Some possible medications for the treatment of IMN have been found using the CMap database. Naringin, with the lowest CMap score, meaningful P value, and specificity score, was predicted as the most likely medication. CONCLUSION: The GEO and CMap databases can be used to understand the molecular changes of IMN and to provide new ideas for medication research. However, medication candidates must undergo clinical and experimental testing.
format Online
Article
Text
id pubmed-9023152
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-90231522022-04-22 Screening of Medications for Idiopathic Membranous Nephropathy Using Glomerular Whole-Genome Sequencing Hou, Yawei Li, Yameng Li, Wenpu Xiao, Zhenwei Comput Math Methods Med Research Article OBJECTIVE: To explore medications that have a therapeutic effect on idiopathic membranous nephropathy (IMN) using the Gene Expression Omnibus (GEO), the Connectivity Map (CMap) database, and bioinformatics approaches. METHODS: IMN patients' glomerular whole-genome sequencing data were retrieved and screened in the GEO database, differentially expressed genes were identified using GEO2R analysis, a PPI network was built in the STRING database, node degree values were calculated, and topological analysis was performed using the degree value to identify core genes. The WebGestalt database was used to perform GO enrichment and KEGG pathway analyses on the core genes. Candidate medications for the therapy of IMN were collected from the CMap database, and the candidate medications were then searched and analyzed. RESULTS: 113 core genes were identified by topological analysis from the 1157 genes that were shown to be differentially expressed. The enrichment analysis identified several important gene functions and signaling pathways related to IMN. Some possible medications for the treatment of IMN have been found using the CMap database. Naringin, with the lowest CMap score, meaningful P value, and specificity score, was predicted as the most likely medication. CONCLUSION: The GEO and CMap databases can be used to understand the molecular changes of IMN and to provide new ideas for medication research. However, medication candidates must undergo clinical and experimental testing. Hindawi 2022-04-14 /pmc/articles/PMC9023152/ /pubmed/35465008 http://dx.doi.org/10.1155/2022/9337088 Text en Copyright © 2022 Yawei Hou et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Hou, Yawei
Li, Yameng
Li, Wenpu
Xiao, Zhenwei
Screening of Medications for Idiopathic Membranous Nephropathy Using Glomerular Whole-Genome Sequencing
title Screening of Medications for Idiopathic Membranous Nephropathy Using Glomerular Whole-Genome Sequencing
title_full Screening of Medications for Idiopathic Membranous Nephropathy Using Glomerular Whole-Genome Sequencing
title_fullStr Screening of Medications for Idiopathic Membranous Nephropathy Using Glomerular Whole-Genome Sequencing
title_full_unstemmed Screening of Medications for Idiopathic Membranous Nephropathy Using Glomerular Whole-Genome Sequencing
title_short Screening of Medications for Idiopathic Membranous Nephropathy Using Glomerular Whole-Genome Sequencing
title_sort screening of medications for idiopathic membranous nephropathy using glomerular whole-genome sequencing
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023152/
https://www.ncbi.nlm.nih.gov/pubmed/35465008
http://dx.doi.org/10.1155/2022/9337088
work_keys_str_mv AT houyawei screeningofmedicationsforidiopathicmembranousnephropathyusingglomerularwholegenomesequencing
AT liyameng screeningofmedicationsforidiopathicmembranousnephropathyusingglomerularwholegenomesequencing
AT liwenpu screeningofmedicationsforidiopathicmembranousnephropathyusingglomerularwholegenomesequencing
AT xiaozhenwei screeningofmedicationsforidiopathicmembranousnephropathyusingglomerularwholegenomesequencing